Sarepta Therapeutics (SRPT)
15.82
-0.39 (2.41%)
Upcoming Events
Latest Headlines
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
July 22, 2026 8:30 AM - BizWire
Sarepta Therapeutics (SRPT) PT Lowered to $20 at Piper Sandler
July 9, 2026 7:11 AM - StreetInsider
Wolfe Research Upgrades Sarepta Therapeutics (SRPT) to Outperform
July 8, 2026 5:07 PM - StreetInsider
H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)
July 1, 2026 6:58 AM - StreetInsider
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 30, 2026 4:25 PM - BizWire
Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
June 30, 2026 11:00 AM - StreetInsider
FDA accepts Sarepta's applications to convert two DMD drugs to full approval
June 30, 2026 8:30 AM - StreetInsider
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
June 30, 2026 8:30 AM - BizWire
Sarepta Therapeutics (SRPT) 5700 contracts of July 20 calls trade
June 18, 2026 6:11 AM - StreetInsider
Form 4 Sarepta Therapeutics, For: Jun 04 Filed by: Boor Kathryn Jean
June 5, 2026 8:11 PM - SEC Filing
Form 4 Sarepta Therapeutics, For: Jun 04 Filed by: Mayo Stephen
June 5, 2026 8:10 PM - SEC Filing
Form 4 Sarepta Therapeutics, For: Jun 04 Filed by: Wigzell Hans Lennart Rudolf
June 5, 2026 8:09 PM - SEC Filing
Form 4 Sarepta Therapeutics, For: Jun 04 Filed by: BEHRENS M KATHLEEN
June 5, 2026 8:08 PM - SEC Filing
Form 4 Sarepta Therapeutics, For: Jun 04 Filed by: Connelly Deirdre P
June 5, 2026 8:07 PM - SEC Filing
Form 4 Sarepta Therapeutics, For: Jun 04 Filed by: Nicaise Claude
June 5, 2026 8:04 PM - SEC Filing
Form 4 Sarepta Therapeutics, For: Jun 04 Filed by: Chambers Michael Andrew
June 5, 2026 8:02 PM - SEC Filing
Form 4 Sarepta Therapeutics, For: Jun 04 Filed by: Barry Richard
June 5, 2026 8:02 PM - SEC Filing
Form S-8 Sarepta Therapeutics,
June 4, 2026 4:56 PM - SEC Filing
Form 8-K Sarepta Therapeutics, For: Jun 04
June 4, 2026 4:30 PM - SEC Filing
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
June 3, 2026 8:30 AM - StreetInsider
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
June 1, 2026 4:30 PM - BizWire
Sarepta Therapeutics (SRPT) PT Lowered to $19 at Evercore ISI
May 15, 2026 7:15 AM - StreetInsider
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
May 13, 2026 4:30 PM - BizWire
Form 13F-HR Sarepta Therapeutics, For: Mar 31
May 13, 2026 4:23 PM - SEC Filing
Sarepta Therapeutics (SRPT) Tops Q1 EPS by 217c
May 6, 2026 4:46 PM - StreetInsider
Form 8-K Sarepta Therapeutics, For: May 06
May 6, 2026 4:11 PM - SEC Filing
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
May 6, 2026 4:05 PM - BizWire
Form 10-Q Sarepta Therapeutics, For: Mar 31
May 6, 2026 4:02 PM - SEC Filing
Form SCHEDULE 13G Sarepta Therapeutics, Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 30, 2026 1:10 PM - SEC Filing
Form SCHEDULE 13G Sarepta Therapeutics, Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC
April 29, 2026 3:14 PM - SEC Filing
Form ARS Sarepta Therapeutics, For: Dec 31
April 24, 2026 4:22 PM - SEC Filing
Form DEFA14A Sarepta Therapeutics,
April 24, 2026 4:11 PM - SEC Filing
Form DEF 14A Sarepta Therapeutics, For: Jun 04
April 24, 2026 4:11 PM - SEC Filing
Full Article List
